8-K: Oscar Health Secures $475M Credit, Reports 2025 Loss, Eyes 2026 Profit

Oscar Health announced a new $475 million revolving credit facility and reported a significant net loss for 2025, while projecting a return to profitability and substantial revenue growth in 2026.

Summary

• Oscar Health, Inc. entered into a new $475.0 million secured three-year revolving credit facility on February 6, 2026, which expires on February 6, 2029.
• The facility includes an expansion option for an additional $100.0 million and its proceeds are designated for general corporate purposes.
• Interest rates for borrowings under the facility will initially be Term SOFR plus 4.50% or Alternate Base Rate plus 3.50%, with adjustments based on the company's Total Net Leverage Ratio starting June 30, 2026.
• The company reported a total revenue of $11.7 billion for the full year 2025, an increase from $9.2 billion in 2024.
• A net loss attributable to Oscar Health, Inc. of $443.2 million was reported for the full year 2025, a significant decline from a net income of $25.4 million in 2024.
• Adjusted EBITDA for 2025 was a loss of $279.8 million, compared to a positive Adjusted EBITDA of $199.2 million in 2024.
• The medical loss ratio increased to 87.4% in 2025 from 81.7% in 2024, primarily due to higher average market morbidity and utilization.
• The SG&A expense ratio improved to 17.5% in 2025 from 19.1% in 2024, attributed to fixed cost leverage, lower exchange fee rates, and disciplined cost management.
• Membership reached a record high of approximately 2.0 million as of December 31, 2025, up from 1.68 million in 2024.
• For the full year 2026, Oscar Health projects total revenue between $18.7 billion and $19.0 billion, a medical loss ratio of 82.4% to 83.4%, and earnings from operations between $250 million and $450 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing with a cautiously optimistic sentiment. While the 2025 financial results show significant losses and an increased medical loss ratio, the strong membership growth, improved SG&A efficiency, and the securing of a substantial revolving credit facility provide a solid foundation for the projected return to profitability and revenue growth in 2026.

Positives

• Secured a new $475.0 million three-year revolving credit facility, enhancing balance sheet flexibility and supporting long-term growth.
• Achieved record membership of approximately 2.0 million as of December 31, 2025, demonstrating strong consumer adoption.
• Improved the SG&A expense ratio to 17.5% in 2025 from 19.1% in 2024, reflecting effective cost management and fixed cost leverage.
• Provided a positive full-year 2026 outlook, projecting a return to profitability with earnings from operations between $250 million and $450 million.
• Forecasts significant revenue growth for 2026, with total revenue expected to be between $18.7 billion and $19.0 billion.

Negatives

• Reported a substantial net loss attributable to Oscar Health, Inc. of $443.2 million for the full year 2025, a significant deterioration from a net income of $25.4 million in 2024.
• Experienced an Adjusted EBITDA loss of $279.8 million in 2025, compared to a positive Adjusted EBITDA of $199.2 million in 2024.
• The medical loss ratio increased to 87.4% in 2025 from 81.7% in 2024, indicating higher medical expenses relative to premiums, driven by increased market morbidity and utilization.
• Loss from operations was $396.4 million in 2025, a sharp decline from earnings of $57.3 million in 2024.

Risks

• Ability to execute strategy and manage growth effectively, including integrating strategic acquisitions.
• Ability to retain and expand the member base.
• Ability to accurately estimate incurred medical expenses or overall market morbidity, or effectively manage medical costs or related administrative costs.
• Unanticipated results of, or changes to, risk adjustment programs or estimates thereof.
• Ability to achieve or maintain profitability in the future.
• Evolving federal or state laws or regulations, including changes with respect to the Patient Protection and Affordable Care Act, expiration or potential renewal of enhanced Advanced Premium Tax Credits, new program integrity rules, potential funding of a cost-sharing reduction program, or other government actions like tariffs.
• Ability to arrange for the delivery of quality care and maintain good relations with brokers and providers.
• Compliance with ongoing, complex, and evolving regulatory requirements, including capital reserve and surplus requirements and applicable performance standards.
• Changes or developments in the regulation of health insurance markets in the United States.
• Compliance with laws, regulations, and standards related to handling of information about individuals or applicable consumer protection laws, especially in government-sponsored programs.
• Ability of health insurance and Health Maintenance Organization subsidiaries to make payments of dividends or distributions to the company.
• Ability to utilize quota share reinsurance to meet capital and surplus requirements and protect against downside risk on medical claims.
• Adverse market conditions resulting in investment portfolio losses or reduced ability to meet financing needs.
• Unfavorable or costly outcomes of lawsuits, audits, investigations, and other third-party claims.
• Incurrence of data security breaches of company or partner information and technology systems.
• Heightened competition in participating markets.
• Ability to attract and retain qualified personnel.
• Ability to detect and prevent material weaknesses or significant control deficiencies in internal controls over financial reporting.
• Uncertainties associated with the utilization of certain artificial intelligence and machine learning models.
• Adverse publicity or other adverse consequences related to the dual-class structure or controlled company status.

Future Outlook

Oscar Health projects a significant turnaround in 2026, anticipating total revenue between $18.7 billion and $19.0 billion and a return to profitability with earnings from operations ranging from $250 million to $450 million. The company also expects an improved medical loss ratio of 82.4% to 83.4% and a lower SG&A expense ratio of 15.8% to 16.3%, driven by new product offerings, AI features, and continued cost management.

Management Comments

• Mark Bertolini, CEO: "2025 was a reset year for the individual market, and we took decisive actions to return to profitability in 2026. Our new suite of affordable products, agentic AI features, and exceptional member experience drove record-high membership – positioning us to achieve significantly improved financial performance in 2026. Oscars growth demonstrates consumers vote where they find value. We are creating a loyal customer base and building a healthcare market that serves the needs of all employers and consumers at every stage of life."
• Scott Blackley, CFO: "We took opportunistic steps to strengthen our balance sheet and optimize our capital structure. The transaction was well supported by a strong syndicate of top-tier banks and completed on favorable terms, further enhancing our balance sheet and providing additional flexibility to fuel long-term growth and accelerate consumer and employer adoption of the individual market."

Industry Context

StockSavvy.ai notes that Oscar Health's focus on 'affordable products' and 'agentic AI features' aligns with broader healthcare industry trends towards value-based care, digital transformation, and personalized member experiences. The record membership growth suggests that Oscar's strategy is resonating with consumers in a competitive individual market, potentially indicating a shift in consumer preferences towards tech-enabled health solutions. The company's emphasis on returning to profitability in 2026, following a 'reset year,' reflects the ongoing challenges and evolving dynamics within the health insurance sector, particularly concerning medical cost management and risk adjustment programs.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark Oscar Health's performance against global industry standards. A detailed comparison would require external data on competitors' medical loss ratios, SG&A expense ratios, and profitability metrics within the health insurance technology sector.

Stakeholder Impact

• Shareholders: Will be impacted by the significant 2025 losses but may see positive sentiment from the 2026 profitability outlook and strengthened balance sheet.
• Customers (Members): Benefit from record membership growth, new affordable products, and agentic AI features, indicating continued focus on member experience and value.
• Lenders: The new revolving credit facility provides a structured lending relationship with specific financial covenants, offering clarity on the company's financial health and obligations.
• Employees: Stock-based compensation is a notable expense, indicating ongoing equity incentive programs, which can impact employee retention and motivation.

Next Steps

• Oscar Health will host a conference call on February 10, 2026, to discuss its financial results.
• The company will file its Annual Report on Form 10-K for the year ended December 31, 2025, with the SEC.
• The company will need to comply with financial covenants related to Direct Policy Premiums, Consolidated Adjusted EBITDA, and Liquidity starting March 31, 2026.
• Additional financial covenants regarding Total Net Leverage Ratio and Fixed Charge Coverage Ratio will commence from March 31, 2027.

Key Dates

Recommendation

The stock recommendation is 'hold' due to the mixed nature of the filing. While the substantial net losses and increased medical loss ratio in 2025 are concerning, the company's strong membership growth, improved SG&A efficiency, and the securing of a new $475 million revolving credit facility provide a more stable financial foundation. The positive 2026 outlook, projecting a return to profitability and significant revenue growth, suggests potential for future recovery. However, the execution risk associated with achieving these ambitious targets and managing medical costs in a dynamic market warrants a cautious approach, advising investors to hold and monitor performance against the stated 2026 guidance.

Keywords

Oscar Health, OSCR, SEC filing, 8-K, financial results, revolving credit facility, healthcare technology, medical loss ratio, EBITDA, membership growth, profitability outlook, corporate finance, health insurance